Last reviewed · How we verify
Placebo to adalimumab
Placebo is an inert substance with no active pharmacological mechanism.
Placebo is an inert substance with no active pharmacological mechanism. Used for Clinical trial control arm (comparator to adalimumab in various inflammatory and autoimmune conditions).
At a glance
| Generic name | Placebo to adalimumab |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo serves as a control comparator in clinical trials and is used to establish the efficacy of active treatments like adalimumab through comparison. It produces no direct biological effect on disease pathways or molecular targets. Any observed clinical benefit from placebo is attributable to the placebo effect—psychological and contextual factors rather than pharmacological action.
Approved indications
- Clinical trial control arm (comparator to adalimumab in various inflammatory and autoimmune conditions)
Common side effects
Key clinical trials
- Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis (PHASE3)
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1, PHASE2)
- An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) (PHASE2)
- Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD (PHASE2)
- Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI (PHASE1, PHASE2)
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
- A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (PHASE3)
- Diabetes Islet Preservation Immune Treatment (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to adalimumab CI brief — competitive landscape report
- Placebo to adalimumab updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI